Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compounds / Tamoxifen

Tamoxifen

Tamoxifen (Nolvadex, Soltamox): FDA-approved uses in breast cancer, its boxed warning on uterine cancer, stroke and blood clots, and WADA status.

FDA-approved, prescription only · Evidence grade A · Reviewed

Approved and studied uses
  • FDA-approvedBreast cancerTreatment, and lowering risk in women at high risk

Tamoxifen (Nolvadex, Soltamox). Selective estrogen receptor modulator.

AFDA-approved, prescription only. Evidence grade A: approved, large human trials.

What is Tamoxifen?

Tamoxifen is an oral selective estrogen receptor modulator (SERM). It blocks estrogen's effect on breast tissue.

Is Tamoxifen FDA-approved?

Tamoxifen was first approved in the United States in 1977 as Nolvadex. Generic tablets are approved for breast cancer treatment, ductal carcinoma in situ, and lowering breast cancer risk in women at high risk. Soltamox, an oral solution, is approved for estrogen receptor positive metastatic breast cancer in adults. It is prescription only, and use to manage steroid side effects is not an approved use.

What does the evidence show for Tamoxifen?

Large randomized trials over several decades, in treatment and risk-reduction settings, support the approved uses.

What are the known risks of Tamoxifen?

The label has a boxed warning: in women with ductal carcinoma in situ and women at high risk of breast cancer, it raised the risk of uterine cancers, stroke and pulmonary embolism, and some cases were fatal. Abnormal vaginal bleeding needs prompt evaluation. WADA prohibits tamoxifen at all times as an anti-estrogenic substance in class S4, hormone and metabolic modulators.

How is Tamoxifen measured?

A tablet, so there is nothing to draw or calculate.

Sources: DailyMed: Tamoxifen citrate tablets label; DailyMed: Soltamox (tamoxifen citrate) oral solution label; USADA: 2026 pocket guide. This profile does not recommend any dose or use.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.